dromlakhani Recommend against dynamic testing with GnRH for hypogonadism evaluation
STEP 1 — Gather Information
Collect symptoms of hypogonadism (e.g., low libido, fatigue, menstrual irregularities) and baseline labs: serum testosterone (or estradiol in females), LH, FSH, prolactin. Record these values and clinical context.
STEP 2 — Rule In / Rule Out
If symptoms and baseline labs do not suggest hypogonadism (normal sex steroids with appropriate gonadotropins), stop evaluation; otherwise proceed to classify the type of hypogonadism.
STEP 3 — Classify or Stratify
Classify as central hypogonadism when testosterone/estradiol is low with low or inappropriately normal LH/FSH; classify as primary hypogonadism when sex steroids are low with elevated LH/FSH.
STEP 4 — Decide
Do not order GnRH dynamic testing; manage based on classification (e.g., consider testosterone replacement for central hypogonadism after excluding hyperprolactinemia, thyroid disease, and other causes).
Clinical Guardrails / Mimics / Pitfalls
- Avoid GnRH testing; it adds no diagnostic value and increases cost and patient burden.
- Do not mistake low LH/FSH with normal testosterone for central hypogonadism without confirming symptoms and excluding exogenous hormone effects.
- Remember that hyperprolactinemia, thyroid dysfunction, and chronic illness can mimic hypogonadism; check prolactin and TSH before attributing low sex steroids to pituitary failure.
- Never initiate testosterone replacement solely on low testosterone without assessing LH/FSH to differentiate central vs primary etiology.
Concrete Clinical Example
A 45‑year‑old man reports decreased libido and erectile dysfunction. Baseline testosterone is 220 ng/dL (low), LH 1.2 IU/L (low‑normal), FSH 1.5 IU/L (low‑normal), prolactin normal. Instead of ordering a GnRH test, the clinician classifies this as central hypogonadism, orders a pituitary MRI, and after ruling out other causes, initiates testosterone replacement.
Source: Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2016-2118